128 related articles for article (PubMed ID: 11061586)
1. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
[TBL] [Abstract][Full Text] [Related]
2. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
[No Abstract] [Full Text] [Related]
3. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
4. Acute endocrine effects of interleukin-12 in cancer patients.
Lissoni P; Rovelli F; Rivolta MR; Frigerio C; Mandalà M; Barni S; Ardizzoia A; Malugani F; Tancini G
J Biol Regul Homeost Agents; 1997; 11(4):154-6. PubMed ID: 9582616
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Lissoni P; Mandalà M; Brivio F
Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
[TBL] [Abstract][Full Text] [Related]
6. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
[TBL] [Abstract][Full Text] [Related]
8. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
10. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
12. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
Lissoni P; Pittalis S; Brivio F; Tisi E; Rovelli F; Ardizzoia A; Barni S; Tancini G; Giudici G; Biondi A
Cancer; 1993 Mar; 71(6):2076-81. PubMed ID: 8443757
[TBL] [Abstract][Full Text] [Related]
13. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
Lissoni P; Malugani F; Bordin V; Conti A; Maestroni G; Tancini G
Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288
[TBL] [Abstract][Full Text] [Related]
14. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
15. Pineal-opioid system interactions in the control of immunoinflammatory responses.
Lissoni P; Barni S; Tancini G; Fossati V; Frigerio F
Ann N Y Acad Sci; 1994 Nov; 741():191-6. PubMed ID: 7825805
[TBL] [Abstract][Full Text] [Related]
16. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G
Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
18. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
Erbağci AB; Herken H; Köylüoglu O; Yilmaz N; Tarakçioglu M
Mediators Inflamm; 2001 Jun; 10(3):109-15. PubMed ID: 11545247
[TBL] [Abstract][Full Text] [Related]
19. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
Eur J Cancer; 1993; 29A(8):1127-32. PubMed ID: 8390845
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer.
Schuler M; Peschel C; Schneller F; Fichtner J; Färber L; Huber C; Aulitzky WE
J Interferon Cytokine Res; 1996 Nov; 16(11):903-10. PubMed ID: 8938565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]